GE HealthCare announces 510(k) submission for CleaRecon DL technology designed to improve image quality in the interventional suite with AI-based reconstruction

GEHC 12.03.2024

Full Press ReleaseSEC FilingsOur GEHC Tweets

About Gravity Analytica

Recent News

  • 01.15.2025 - University of California San Francisco and GE HealthCare Launch a Joint Research Program to Drive Innovations in Imaging, Brain Health and Precision Oncology
  • 01.14.2025 - Sutter Health and GE HealthCare enter strategic partnership to benefit patients, physicians and clinicians with advanced, AI-powered imaging
  • 12.12.2024 - GE HealthCare to announce fourth quarter and full year 2024 results on February 13, 2025

Recent Filings

  • 12.12.2024 - 8-K Current report
  • CleaRecon DL* is designed to improve cone-beam computed tomography (CBCT) image quality by removing streaks and help clinicians improve their confidence in image interpretation when analyzing CBCT data

CHICAGO--(BUSINESS WIRE)--Dec. 3, 2024--GE HealthCare(Nasdaq: GEHC) announced today the 510(k) submission to theU.S. Food and Drug Administrationfor CleaRecon DL, deep learning technology, designed to improve the quality of cone-beam computed tomography (CBCT) images by bringing artificial intelligence (AI)-based 3D reconstruction to the interventional suite. This technology, which is pending 510(k) clearance, will be demonstrated at the Radiological Society of North America’s (RSNA) 2024 Annual Meeting taking place fromDecember 1-4inChicago.

As demand for minimally invasive procedures continues to grow,GE HealthCareis committed to helping clinicians use image guidance technologies to their full potential by removing barriers with the goal of helping providers achieve better clinical and operational outcomes.

To be available on AlliaTM Image-Guided Solutions (IGS) Systems, CleaRecon DL is designed to use AI-based reconstruction to improve image quality by removing streaks without introducing additional artifacts. It is also designed to improve CBCT analysis through clear images. This technology aims to advance the company’s vision to accelerate CBCT adoption in daily practice.

“GE HealthCare has been a leader in CBCT for more than two decades - offering continued innovation through offerings such as augmented guidance solutions designed to improve procedure outcomes, as well as developing a wide-bore platform capable of acquiring CBCT with obese patients, even with their arms down,” saidArnaud Marie, General Manager, Global Intervention atGE HealthCare. “Over the years, artifacts created in scans through natural movement of the body and the distribution of contrast have posed another significant challenge to clinicians when obtaining CBCT images - posing a major barrier to adoption of CBCT technology. We designed CleaRecon DL to address this challenge so physicians and their patients can benefit from this advanced imaging technology.”

In addition to CleaRecon DL,GE HealthCareis also introducing OnWatch Predict, predictive monitoring of interventional image-guided systems to provide enhanced service and increase system availability for on-time diagnosis, invasive procedures and treatments. Combining ongoing system diagnosis with user interface monitoring, image chain health and X-ray generation, OnWatch Predict is designed to forecast component failure, allowing clinicians to schedule service before an issue occurs with the system and limiting unplanned downtime.

For more information on GE HealthCare’s Allia IGS platform and the company’s commitment to advancing the practice of image guided therapy with artificial intelligence and digitization tools, visit GE HealthCare Booth #7330,RSNA 2024 press kit, or theRSNA 2024 events page.

*CleaRecon DL1,21) Designed to be used with AlliaTM systems.2) CleaRecon DL is an option using deep learning in 3DXR. 510(k) and CE mark pending. Not available for sale in US or EU.

AboutGE HealthCare Technologies Inc.

GE HealthCareis a leading global medical technology, pharmaceutical diagnostics, and digital solutions innovator, dedicated to providing integrated solutions, services, and data analytics to make hospitals more efficient, clinicians more effective, therapies more precise, and patients healthier and happier. Serving patients and providers for more than 125 years,GE HealthCareis advancing personalized, connected, and compassionate care, while simplifying the patient’s journey across the care pathway. Together our Imaging, Advanced Visualization Solutions, Patient Care Solutions, andPharmaceutical Diagnosticsbusinesses help improve patient care from diagnosis, to therapy, to monitoring. We are a$19.6 billionbusiness with approximately 51,000 colleagues working to create a world where healthcare has no limits.

Follow us onLinkedIn,X,Facebook,Instagram, andInsightsfor the latest news, or visit our websitehttps://www.gehealthcare.comfor more information.

View source version onbusinesswire.com:https://www.businesswire.com/news/home/20241203284278/en/

Julie AllisonSenior CommunicationsManager(347) 327-0836julie.allison@gehealthcare.com

Source:GE HealthCare

Please be aware that the following content has been generated by an AI system and may contain errors, inconsistencies, or outdated information. It is provided as-is without any warranties or guarantees of accuracy. We strongly recommend using this content as a starting point for further research and consultation with relevant experts or authorities. We disclaim any liability for damages or losses resulting from the use or reliance on this content.Please note that this is a beta version of the Gravity Analytica LLC’s AI Service which isstill undergoing final testing before its official release. Theplatform, its software and all content found on it are provided on an“as is” and “as available” basis. Gravity Analytica LLC does not give any warranties,whether express or implied, as to the suitability or usability of thisservice, webpage, or its software or any of its content.Should you encounter any bugs, glitches, lack of functionality orother problems on the website, please let us know immediately so wecan rectify these accordingly. Your help in this regard is greatlyappreciated! You can write to us at this addressteam@gravityanalytica.com